May 6, 2020 / 1:58 PM / a month ago

BRIEF-Eyepoint Pharmaceuticals Q1 Loss Per Share $0.11

May 6 (Reuters) - EyePoint Pharmaceuticals Inc:

* EYEPOINT PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE DEVELOPMENTS

* Q1 LOSS PER SHARE $0.11

* Q1 REVENUE $7.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $7.3 MILLION

* Q1 EARNINGS PER SHARE ESTIMATE $-0.10 — REFINITIV IBES DATA

* EYEPOINT PHARMACEUTICALS - HAVE BEEN NO DISRUPTIONS TO SUPPLY CHAINS FOR YUTIQ & DEXYCU, CO CONTINUES TO PRODUCE FINISHED PRODUCT FOR COMMERCIAL SALE

* EYEPOINT - EXPECTS PRODUCT DEMAND TO CONTINUE AT CURRENT DECREASED LEVELS UNTIL COVID-19 RELATED RESTRICTIONS ON ELECTIVE SURGERIES, OFFICE VISITS LIFTED

* EYEPOINT - EXPECT CASH & CASH EQUIVALENTS WITH PROJECTED CASH INFLOWS FROM ANTICIPATED YUTIQ & DEXYCU PRODUCT SALES CAN FUND OPERATING PLAN INTO 2021

* EYEPOINT PHARMACEUTICALS - CONTINUES TO ASSESS ADDITIONAL CASH CONSERVATION MEASURES TO SUPPORT OPERATION THROUGH COVID-19 PANDEMIC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below